Over 1 Million patients treated worldwide with Xarelto ® 10
following Total Hip and Total Knee Replacement surgery APPROVED
Reduce the risk
Venous Thromboembolism clinically presenting as deep vein thrombosis or pulmonary embolism remains a major cause of morbidity and mortality worldwide.
Why have so many professionals put their trust in Xarelto ® 10 to reduce the risk of VTE?
* * Extensively studied: investigated in 9 successful Phase III studies * Increased protection: against DVT, PE and death 2 * * Reassuring safety: comparable to enoxaparin 2 * Convenience: one 10 mg tablet daily with no dose adjustment for age, gender or body weight 3 * Sustained confidence: protection from hospital to home 2 * European Union's EMA and US FDA approved * Xarelto ® 10 is from Bayer HealthCare: innovator and leader in many therapeutic categories REFERENCES: 1. Cohen AT, Dobromirski M, Lin S-l, Wills JO. Venous Thromboembolism: The Magnitude of the Problem in Europe and the World. Adv Venous Arterial Thromb 2011;1(2):39-45. 2. Duggan ST, Scott LJ, Plosker GL. Rivaroxaban. A Review of its Use for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement Surgery. Drugs 2009; 69 (13):1829-1851. 3. XARELTO ® 10 Package Insert. * DVT - deep vein thrombosis PE - pulmonary embolism VTE - venous thromboembolism. For full information, please refer to the package insert approved by the Medicines Regulatory Authority (MCC). S4 XARELTO ® 10 (Film-coated tablets). Reg. No.: 42/8.2/1046. Each fi lm-coated tablet contains rivaroxaban 10 mg. PHARMACOLOGICAL CLASSIFICATION: A. 8.2 Anticoagulants. INDICATION: Prevention of venous thromboembolism (VTE) in patients undergoing major orthopaedic surgery of the lower limbs. HCR: Bayer (Pty) Ltd, Reg. No.: 1968/011192/07, 27 Wrench Road, Isando, 1609. Tel: 011 921 5044. Fax: 011 921 5041. DATE: December 2011. L.ZA.GM.2011.03.60